Sanofi said it will not seek approval of amlitelimab in atopic dermatitis, calling the OX40-ligand monoclonal antibody unlikely to provide a meaningful improvement over current standards of care for moderate-to-severe patients. The move marks a pipeline about-face after the company had previously positioned amlitelimab as a potential successor to Regeneron’s Dupixent. The decision also extends a broader reprioritization of Sanofi’s immunology portfolio, as the company continues reassessing how amlitelimab fits into its late-stage development plans and resourcing.